Lymphoid proliferations associated with human immunodeficiency virus infection

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 3, 2013, Pages 360-370

  Chadburn, Amy ^a   Abdul Nabi, Anmaar M ^a   Teruya, Bryan Scott ^a   Lo, Amy A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; PATHOLOGY; VIROLOGY;

HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84874727814     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0095-RA     Document Type: Article

References (164)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Immunodeficiency-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press; 2001:255. World Health Organization Classification of Tumours.
2. Raphael M, Said J, Dorisch B, Cesarman E, Harris N. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon, France: IARC Press; 2008:340-342. World Health Organization Classification of Tumours; vol 2.
3. Nasr SA, Brynes RK, Garrison CP, Chan WC. Peripheral T-cell lymphoma in a patient with acquired immune deficiency syndrome. Cancer. 1988;61(5):947-951.
4. Lust JA, Banks PM, Hooper WC, et al. T-cell non-Hodgkin lymphoma in human immunodeficiency virus-1-infected individuals. Am J Hematol. 1989;31(3):181-187.
5. Castillo J, Perez K, Milani C, Dezube BJ, Pantanowitz L. Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review. J HIV Ther. 2009;14(2):34-40.
6. Boulanger E, Meignin V, Baia M, et al. Mucosa-associated lymphoid tissue lymphoma in patients with human immunodeficiency virus infection. Br J Haematol. 2008;140(4):470-474.
7. Shorrock K, Ellis IO, Finch RG. T-cell lymphoma associated with human immunodeficiency virus (HIV) infection. Histopathology. 1990;16(2):189-191.
8. Knowles DM, Chadburn A. Lymphadenopathy and the lymphoid neoplasms associated with the acquired immune deficiency syndrome. In: Knowles DM, ed. Neoplastic Hematopathology. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:987-1089.
9. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35.
10. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67.
11. Mathur-Wagh U, Enlow RW, Spigland I, et al. Longitudinal study of persistent generalised lymphadenopathy in homosexual men: relation to acquired immunodeficiency syndrome. Lancet. 1984;1(8385):1033-1038.
12. Guarda LA, Butler JJ, Mansell P, Hersh EM, Reuben J, Newell GR. Lymphadenopathy in homosexual men. Morbid anatomy with clinical and immunologic correlations. Am J Clin Pathol. 1983;79(5):559-568.
13. Metroka CE, Cunningham-Rundles S, Pollack MS, et al. Generalized lymphadenopathy in homosexual men. Ann Intern Med. 1983;99(5):585-591.
14. Miller B, Stansfield SK, Zack MM, et al. The syndrome of unexplained generalized lymphadenopathy in young men in New York City. Is it related to the acquired immune deficiency syndrome? JAMA. 1984;251(2):242-246.
15. Control CfD. Persistent, generalized lymphadenopathy among homosexual males. MMWR Morb Mortal Wkly Rep. 1982;31(19):249-251.
16. Chan WC, Brynes RK, Spira TJ, et al. Lymphocyte subsets in lymph nodes of homosexual men with generalized unexplained lymphadenopathy: correlation with morphology and blood changes. Arch Pathol Lab Med. 1985;109(2):133-137.
17. Fernandez R, Mouradian J, Metroka C, Davis J. The prognostic value of histopathology in persistent generalized lymphadenopathy in homosexual men. N Engl J Med. 1983;309(3):185-186.
18. Pileri S, Rivano MT, Raise E, et al. The value of lymph node biopsy in patients with the acquired immunodeficiency syndrome (AIDS) and the AIDSrelated complex (ARC): a morphological and immunohistochemical study of 90 cases. Histopathology. 1986;10(11):1107-1129.
19. Ioachim HL, Cronin W, Roy M, Maya M. Persistent lymphadenopathies in people at high risk for HIV infection: clinicopathologic correlations and longterm follow-up in 79 cases. Am J Clin Pathol. 1990;93(2):208-218.
20. Chadburn A, Metroka C, Mouradian J. Progressive lymph node histology and its prognostic value in patients with acquired immunodeficiency syndrome and AIDS-related complex. Hum Pathol. 1989;20(6):579-587.
21. Biberfeld P, Ost A, Porwit A, et al. Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A. 1987;95(1):47-65.
22. Schuurman HJ, Kluin PM, Gmelig Meijling FH, Van Unnik JA, Kater L. Lymphocyte status of lymph node and blood in acquired immunodeficiency syndrome (AIDS) and AIDS-related complex disease. J Pathol. 1985;147(4):269-280.
23. Gerstoft J, Pallesen G, Mathiesen L, et al. Stages in LAV/HTLV-III lymphadenitis, II: correlation with clinical and immunological findings. Scand J Immunol. 1987;25(1):93-99.
24. Burton GF, Keele BF, Estes JD, Thacker TC, Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol. 2002;14(4):275-284.
25. Burns BF, Wood GS, Dorfman RF. The varied histopathology of lymphadenopathy in the homosexual male. Am J Surg Pathol. 1985;9(4):287-297.
26. Turner RR, Levine AM, Gill PS, Parker JW, Meyer PR. Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. Am J Surg Pathol. 1987;11(8):625-632.
27. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis, I: histological and immunohistological classification. Scand J Immunol. 25(1):83-91.
28. Said JW. AIDS-related lymphadenopathies. Semin Diagn Pathol. Nov 1988;5(4):365-375.
29. Sohn CC, Sheibani K, Winberg CD, Rappaport H. Monocytoid B lymphocytes: their relation to the patterns of the acquired immunodeficiency syndrome (AIDS) and AIDS-related lymphadenopathy. Hum Pathol. 1985;16(10):979-985.
30. Wood GS, Garcia CF, Dorfman RF, Warnke RA. The immunohistology of follicle lysis in lymph node biopsies from homosexual men. Blood. 1985;66(5):1092-1097.
31. Diebold J, Marche C, Audouin J, et al. Lymph node modification in patients with the acquired immunodeficiency syndrome (AIDS) or with AIDS related complex (ARC). A histological, immuno-histopathological and ultrastructural study of 45 cases. Pathol Res Pract. 1985;180(6):590-611.
32. Raphael M, Pouletty P, Cavaille-Coll M, et al. Lymphadenopathy in patients at risk for acquired immunodeficiency syndrome. Histopathology and histochemistry. Arch Pathol Lab Med. 1985;109(2):128-132.
33. Said JW, Shintaku IP, Teitelbaum A, Chien K, Sassoon AF. Distribution of Tcell phenotypic subsets and surface immunoglobulin-bearing lymphocytes in lymph nodes from male homosexuals with persistent generalized adenopathy: an immunohistochemical and ultrastructural study. Hum Pathol. 1984;15(8):785-790.
34. Baroni CD, Vitolo D, Uccini S. Immunohistopathogenesis of persistent generalized lymphadenopathy in HIV-positive patients. Ric Clin Lab. 1990;20(1):1-10.
35. Schuurman HJ, Krone WJ, Broekhuizen R, Goudsmit J. Expression of RNA and antigens of human immunodeficiency virus type-1 (HIV-1) in lymph nodes from HIV-1 infected individuals. Am J Pathol. 1988;133(3):516-524.
36. Wood GS, Burns BF, Dorfman RF, Warnke RA. Fatal post-transfusion acquired immunodeficiency in a heterosexual man: quantitative lymph node immunopathology. Hum Pathol. 1988;19(2):236-238.
37. Porwit A, Bottiger B, Pallesen G, Bodner A, Biberfeld P. Follicular involution in HIV lymphadenopathy: a morphometric study. APMIS. 1989;97(2):153-165.
38. Walewska-Zielecka B, Nowoslawski A. HIV lymphadenopathy - a histopathological and immunomorphological study of 65 cases. Pol J Pathol. 1995;46(4):211-217.
39. Grouard G, Clark EA. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis. Curr Opin Immunol. 1997;9(4):563-567.
40. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol. 1996;50:825-854.
41. Zhang ZQ, Schuler T, Cavert W, et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1999;96(9):5169-5172.
42. Huber G, Banki Z, Lengauer S, Stoiber H. Emerging role for complement in HIV infection. Curr Opin HIV AIDS. 2011;6(5):419-426.
43. Orenstein JM, Feinberg M, Yoder C, et al. Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS. 1999;13(16):2219-2229.
44. Mueller BU, Sei S, Anderson B, et al. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. J Pediatr. 1996;129(3):410-418.
45. Ehrhard S, Wernli M, Kaufmann G, et al. Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals. Infection. 2008;36(2):120-129.
46. Laman JD, Claassen E, Van Rooijen N, Boersma WJ. Immune complexes on follicular dendritic cells as a target for cytolytic cells in AIDS. AIDS. 1989;3(8):543-544.
47. Li Q, Schacker T, Carlis J, Beilman G, Nguyen P, Haase AT. Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy. J Infect Dis. 2004;189(4):572-582.
48. Bart PA, Rizzardi GP, Tambussi G, et al. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS. 2000;14(13):1887-1897.
49. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276(5314):960-964.
50. Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis. 2002;186(8):1092-1097.
51. Shugar JM, Som PM, Jacobson AL, Ryan JR, Bernard PJ, Dickman SH. Multicentric parotid cysts and cervical adenopathy in AIDS patients: a newly recognized entity: CT and MR manifestations. Laryngoscope. 1988;98(7):772-775.
52. Finfer MD, Schinella RA, Rothstein SG, Persky MS. Cystic parotid lesions in patients at risk for the acquired immunodeficiency syndrome. Arch Otolaryngol Head Neck Surg. 1988;114(11):1290-1294.
53. DiGiuseppe JA, Corio RL, Westra WH. Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol. 1996;8(3):232-237.
54. Kreisel FH, Frater JL, Hassan A, El-Mofty SK. Cystic lymphoid hyperplasia of the parotid gland in HIV-positive and HIV-negative patients: quantitative immunopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(4):567-574.
55. Dave SP, Pernas FG, Roy S. The benign lymphoepithelial cyst and a classification system for lymphocytic parotid gland enlargement in the pediatric HIV population. Laryngoscope. 2007;117(1):106-113.
56. Michelow P, Dezube BJ, Pantanowitz L. Fine needle aspiration of salivary gland masses in HIV-infected patients [published online ahead of print January 6, 2011]. Diagn Cytopathol. doi:10.1002/dc.21597.
57. Terry JH, Loree TR, Thomas MD, Marti Jr. Major salivary gland lymphoepithelial lesions and the acquired immunodeficiency syndrome. Am J Surg. 1991;162(4):324-329.
58. Syebele K, Butow KW. Comparative study of the effect of antiretroviral therapy on benign lymphoepithelial cyst of parotid glands and ranulas in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(2):205-210.
59. Lowenthal DA, Filippa DA, Richardson ME, Bertoni M, Straus DJ. Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer. 1987;60(10):2454-2458.
60. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985;83(1):27-33.
61. PerlowLS, Taff ML, Orsini JM, et al. Kaposi's sarcoma in a young homosexual man: association with angiofollicular lymphoid hyperplasia and a malignant lymphoproliferative disorder. Arch Pathol Lab Med. 1983;107(10):510-513.
62. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-1869.
63. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-1280.
64. Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+multicentric Castleman disease (MCD). Histopathology. 2008;53(5):513-524.
65. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412.
66. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96(8):4546-4551.
67. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgMk) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136.
68. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60(12):1350-1357.
69. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156(3):743-749.
70. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi's sarcomaassociated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem. 1997;272(31):19625-19631.
71. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034-4043.
72. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627-3634.
73. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med. 2007;46(11):771-774.
74. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIVinfected patients. Blood. 2000;96(6):2069-2073.
75. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97(8):2526-2527.
76. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009;20(4):775-779.
77. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4(1):16-21.
78. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-2336.
79. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730-2734.
80. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer. 2010;116(23):5507-5516.
81. Stebbing J, Duru O, Bower M. Non-AIDS-defining cancers. Curr Opin Infect Dis. 2009;22(1):7-10.
82. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
83. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32(5):527-533.
84. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA. 2011;305(14):1450-1459.
85. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117(5):1089-1096.
86. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-762.
87. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
88. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187-194.
89. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60(12):1365-1372.
90. Panarelli NC, Furman RR, Wang YL, Elstrom R, Cohen JA, Chadburn A. NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. J Hematop. 2010;3(1):35-40.
91. Mantina H, Wiggill TM, Carmona S, Perner Y, Stevens WS. Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr. 2010;53(5):656-660.
92. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165(10):1143-1153.
93. Carbone A, Spina M, Gloghini A, Tirelli U. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol. 2011;86(2):170-179.
94. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113(23):5737-5742.
95. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786-3791.
96. Spina M, Berretta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am. 2003;17(3):843-858.
97. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13(7):1758-1767.
98. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndromerelated lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82(2):619-624.
99. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116(25):5600-5604.
100. Raphael M, Gentilhomme O, Tulliez M, Byron PA, Diebold J; French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1991;115(1):15-20.
101. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissue. 4th ed. Lyon, France: IARC Press; 2008:262-264. World Health Organization Classification of Tumours; vol 2.
102. Davi F, Delecluse HJ, Guiet P, et al Burkitt's Lymphoma Study Group. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. J Clin Oncol. 1998;16(12):3788-3795.
103. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G. Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol. 2010;134(1):127-138.
104. Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood. 1993;81(1):166-176.
105. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2003;17(3):785-820.
106. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1998;91(3):747-755.
107. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 50 noncoding region of the BCL-6 gene in acquired immunodeficiency syndromerelated non-Hodgkin's lymphomas. Blood. 1997;89(10):3755-3762.
108. Bellan C, De Falco G, Lazzi S, Leoncini L. Pathologic aspects of AIDS malignancies. Oncogene. 2003;22(42):6639-6645.
109. De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22(40):6214-6219.
110. Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood. 2011;117(13):3596-3608.
111. De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Semin Cancer Biol. 2009;19(6):401-406.
112. Leucci E, Onnis A, Cocco M, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer. 2010;126(6):1316-1326.
113. Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216(4):440-450.
114. Onnis A, De Falco G, Antonicelli G, et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One. 2010;5(9):e12960. doi:10.1371/journal.pone.0012960.
115. Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS. 2008;22(3):175-187.
116. Noy A. Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol. 2010;22(5):443-448.
117. Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med. 1988;108(5):744-753.
118. Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. Blood. 1994;84(2):397-402.
119. Mathew S, Gogineni S, Cesarman E, Knowles DM, Chadburn A. MYC, BCL6 and BCL2 genetic alterations and associated phenotypes of AIDS-related (AR) diffuse large B cell lymphomas (DLBCLs) suggest biologic differences with immunocompetent (IC) DLBCLs. Mod Pathol. 2010;23(suppl 1s):377A; doi:10.1038/modpathol.2010.23.
120. Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R. Frequent cmyc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood. 1988;72(2):667-671.
121. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 2003;102(5):1833-1841.
122. Capello D, Martini M, Gloghini A, et al. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica. 2008;93(8):1178-1185.
123. Capello D, Scandurra M, Poretti G, et al. Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol. 2010;148(2):245-255.
124. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC. Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr. 2010;54(1):18-26.
125. Chadburn A, Silver S, Pasqualucci L, et al. Comparison of AIDS-related diffuse large B cell lymphomas (AR-DLBCLs) and Immunocompetent (IC) DLBCLs suggest biologic differences. Mod Pathol. 2009;22:257A.
126. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653-4659.
127. Alacacioglu I, Ozcan MA, Ozkal S, et al. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology. 2009;14(2):84-89.
128. Hong J, Park S, Park J, et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011;52(10):1904-1912.
129. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
130. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
131. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large Bcell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
132. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
133. Xicoy B, Ribera JM, Mate JL, et al. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. Leuk Lymphoma. 2010;51(11):2063-2069.
134. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD; National Institute of Allergy and Infectious Diseases. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1998;16(11):3601-3606.
135. Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029-2037.
136. Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257-265.
137. Camilleri-Broet S, Davi F, Feuillard J, et al The French Study Group for HIV-Associated Tumors. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. Hum Pathol. 1997;28(3):367-374.
138. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDSrelated primary central nervous system lymphoma. Lancet. 1991;338(8773):969-973.
139. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413-1420.
140. Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-2053.
141. Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon, France: IARC Press; 2008:256-257. World Health Organization Classification of Tumours; vol 2.
142. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29(12):1633-1641.
143. Hansra D, Montague N, Stefanovic A, et al. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol. 2010;134(5):710-719.
144. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23(7):991-999.
145. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686-1694.
146. Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002;119(3):622-628.
147. Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132(4):597-605.
148. Chang CC, Zhou X, Taylor JJ, et al. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009;2:47.
149. Isaacson PG, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:258-259. World Health Organization Classification of Tumours; vol 2.
150. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332(18):1181-1185.
151. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related bodycavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
152. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88(2):645-656.
153. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401-1416.
154. Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7(1):17-27.
155. Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant. 2008;8(3):707-710.
156. Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia. 1999;13(5):664-670.
157. Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon, France: IARC Press; 2008:260-261. World Health Organization Classification of Tumours; vol 2.
158. Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115- 4121.
159. Fais F, Gaidano G, Capello D, et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia. 1999;13(7):1093-1099.
160. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372-4380.
161. Wang X, Nathan S, Catchatourian R, Richter H, 3rd, Kovarik P. Polymorphic lymphoid proliferation presenting as ileocecal intussusception. Ann Hematol. 2007;86(6):453-454.
162. Tao J, Valderrama E. Epstein-Barr virus-associated polymorphic B-cell lymphoproliferative disorders in the lungs of children with AIDS: a report of two cases. Am J Surg Pathol. 1999;23(5):560-566.
163. Nador RG, Chadburn A, Gundappa G, Cesarman E, Said JW, Knowles DM. Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol. 2003;27(3):293-302.
164. Martin SI, Zukerberg L, Robbins GK. Reactive Epstein-Barr virus-related polyclonal lymphoproliferative disorder in a patient with AIDS. Clin Infect Dis. 2005;41(8):e76-79.